Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > LATEST
LATEST
-
BUSINESS Sanofi’s ITP Drug Wayrilz Goes on Sale in Japan
October 21, 2026
-
BUSINESS Maruho Secures South Korean Rights to Incyte’s Ruxolitinib Cream
October 21, 2026
-
BUSINESS CMIC Turns to AI to Hear Job Applicants in Their Own Words
October 21, 2026
-
BUSINESS Arthur D. Little Urges Pricing Revamp to Spur Regenerative Medicine in Japan
October 21, 2026
-
ORGANIZATION Ex-JMA Vice President, Lawmaker Hanyuda Remembered at Memorial Service
October 21, 2026
-
BUSINESS Entyvio PIV Trial Links Disease Clearance to 70% Lower UC Complication Risk
October 21, 2026
-
BUSINESS Toho Subsidiary Suffers Data Breach, HCP Info Exposed
October 20, 2026
-
REGULATORY LDP Health Chief Demands CEA Overhaul, Backs Freeze on Price Cuts
October 20, 2026
-
BUSINESS Veritas, Toray Pin Down Hit Compounds for PCSK9 mRNA Drugs
October 20, 2026
-
BUSINESS Insmed’s Brinsupri Hits Japan Market for NCFB
October 20, 2026
-
BUSINESS Ex-Alfresa Chairman Arata Watanabe Dies at 85
October 20, 2026
-
COMMENTARY Lp(a) Drugs Face Next Test in Quest to Cut Cardiovascular Risk
October 19, 2026
-
REGULATORY Japan Eyes Spring 2027 Plan to Address Drug Discovery Workforce Needs
October 19, 2026
-
BUSINESS TS Alfresa-Backed Drone Council Inks Pact with Hiroshima
October 19, 2026
-
BUSINESS Santen to Seek Bankruptcy for Chinese Subsidiary
October 19, 2026
-
BUSINESS Toho Invests in Keio Offshoot AdipoSeeds
October 19, 2026
-
BUSINESS Amgen, JASSO Team Up on Obesity Research and Care
October 19, 2026
-
BUSINESS Sanwa Kagaku to Resume Kumamoto Production on October 19
October 19, 2026
-
REGULATORY Minister Lauds Stemirac after Panel Backs Full Approval
October 19, 2026
-
BUSINESS J&J Launches Stelara SC Vial for Pediatric Crohn’s Disease
October 19, 2026
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…